Sammanfattning
Introduction and purpose - Antiresorptive therapies effectively
reduce the incidence of skeletal fractures and bone pain
in patients with metastatic bone cancer and multiple myeloma.
Patients in high dose antiresorptive treatment are at high risk of
developing osteonecrosis of the jaws (ONJ) after tooth extraction.
Presently, the antiresorptive treatment is discontinued in relation
to the tooth extraction, known as drug holiday - even though it is
unknown whether a drug holiday plays a role for the development
of ONJ after tooth extraction with primary mucosal cover. The
purpose of this article is to clarify the importance of a high dose
antiresorptive drug holiday in relation to tooth extraction for the
development of ONJ.
Methods - Keywords and search were made in collaboration
with Copenhagen Trial Unit and included literature in all relevant
scientific databases.
Review of the literature - We did not find any trials or systematic
reviews, testing whether antiresorptive drug holiday could
reduce the development of ONJ in relation to tooth extraction in
cancer patients at high dose antiresorptive treatment.
Conclusion - At present there is no evidence for or against the
use of a high-dose antiresorptive drug holiday in relation to tooth
extraction with primary mucosal cover for the development of ONJ.